The current price of IBRX is $8.93 — it has increased by 7.72% since the previous close. Data as of Nov 4, 2026.
IBRX is up 5.31% over the past week, down 13.22% over the past month and up 329.33% over the past year. The price is above its 200-day moving average of $7.94.
Of the 4 analysts covering ImmunityBio, Inc., 1 rates it a strong buy and 3 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
ImmunityBio, Inc. has a market capitalization of $9.46B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, ImmunityBio, Inc. posted a loss of $0.22 per share against an estimate of -$0.08, missing expectations by 175.00%. Upcoming reports are listed in the earnings calendar.
ImmunityBio, Inc. reported revenue of $51.24M in its most recent quarter, which has increased by 93.91% compared with the same quarter a year earlier. Analysts had expected $49.7M.
ImmunityBio, Inc. has not paid any dividends over the past year.
Companies most comparable to ImmunityBio, Inc. include Moderna, Inc., BioNTech SE, Legend Biotech Corporation, Iovance Biotherapeutics, Inc. and Vir Biotechnology, Inc.
In the latest trading session IBRX moved between $8.21 and $8.95, a range of 8.34% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of ImmunityBio, Inc. shows a buy rating today and a strong buy rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for ImmunityBio, Inc. is buy. Technical ratings are indicators, not investment advice.
Over the past 52 weeks IBRX has traded between $1.95 and $12.43. The current price is 28.16% below its 52-week high.
Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.